Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma
Abstract Metastatic melanoma can be treated with anti-PD-1 monotherapy or in combination with anti-CTLA-4 or anti-Lag3. However, combination therapy is associated with a high risk of toxicity. Recently, we reported that high plasma soluble CD27 (sCD27) levels reflect the intratumoral interaction of...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer Nature
2025-03-01
|
| Seri Bilgileri: | EMBO Molecular Medicine |
| Konular: | |
| Online Erişim: | https://doi.org/10.1038/s44321-025-00203-9 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
